Stereotactic Body Radiotherapy Using CyberKnife® for Localized Low- and Intermediate-risk Prostate Cancer: Initial Report on a Phase I/II Trial

被引：3
|
作者：
Nakamura, Ryosuke [1 ]
Hirata, Takero [1 ]
Suzuki, Osamu [1 ]
Otani, Keisuke [1 ]
Kai, Naoki [1 ]
Hatano, Koji [2 ]
Fujita, Kazutoshi [2 ]
Uemura, Motohide [2 ]
Imamura, Ryoichi [2 ]
Tanaka, Kazunori [1 ]
Yoshioka, Yasuo [3 ]
Nonomura, Norio [2 ]
Ogawa, Kazuhiko [1 ]
机构：
[1] Osaka Univ, Grad Sch Med, Dept Radiat Oncol, 2-2 Yamada Oka, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Grad Sch Med, Dept Urol, Osaka, Japan
[3] Japanese Fdn Canc Res, Canc Inst Hosp, Dept Radiat Oncol, Tokyo, Japan
来源：
ANTICANCER RESEARCH | 2020年 / 40卷 / 04期
关键词：
SBRT; CyberKnife; prostate cancer; INTENSITY-MODULATED RADIOTHERAPY; FRACTIONATION; BRACHYTHERAPY;
D O I：
10.21873/anticanres.14162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: The present study aimed to evaluate the toxicity and efficacy of stereotactic body radiotherapy (SBRT) for localized prostate cancer. Patients and Methods: We investigated 25 patients treated with SBRT of 35 Gy per five fractions from May 2014 to March 2015. Results: The median age of patients was 70 years, four (16%) patients were low risk and 21 (84%) were intermediate risk. Seven (28%) patients received neoadjuvant androgen-deprivation therapy. The median follow-up time was 53 months. Grade 2 acute and late genitourinary toxicities were observed in five (20%) and two (8%) patients and there were no Grade 2 gastrointestinal toxicities. There were no Grade 3 or higher acute or late toxicities at 2 years follow-up. The biochemical relapse-free survival rate at 2 years was 100%. Conclusion: SBRT of 35 Gy per five fractions is a promising treatment method in the short term for prostate cancer.
引用
收藏
页码：2053 / 2057
页数：5
相关论文
共 50 条
  • [1] Stereotactic Body Radiotherapy for Low- and Intermediate-Risk Prostate Cancer
    Kishan, Amar U.
    King, Christopher R.
    SEMINARS IN RADIATION ONCOLOGY, 2017, 27 (03) : 268 - 278
  • [2] Stereotactic body radiotherapy with CyberKnife® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial
    Borzillo, Valentina
    Scipilliti, Esmeralda
    Pezzulla, Donato
    Serra, Marcello
    Ametrano, Gianluca
    Quarto, Giuseppe
    Perdona, Sisto
    Rossetti, Sabrina
    Pignata, Sandro
    Crispo, Anna
    Di Gennaro, Piergiacomo
    D'Alesio, Valentina
    Arrichiello, Cecilia
    Buonanno, Francesca
    Mercogliano, Simona
    Russo, Antonio
    Tufano, Antonio
    Di Franco, Rossella
    Muto, Paolo
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [3] Hypofractionated stereotactic body radiotherapy in low- and intermediate-risk prostate carcinoma
    Kim, Hun Jung
    Phak, Jeong Hoon
    Kim, Woo Chul
    RADIATION ONCOLOGY JOURNAL, 2016, 34 (04): : 260 - 264
  • [4] Outcomes of a Dose-Escalated Stereotactic Body Radiation Phase I/II Trial for Patients With Low- and Intermediate-Risk Prostate Cancer
    Rana, Zaker
    Potters, Louis
    Lee, Lucille
    Cox, Brett
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2018, 101 (02): : E8 - E8
  • [5] STEREOTACTIC BODY RADIATION THERAPY IN LOW- AND INTERMEDIATE-RISK PROSTATE CANCER: RESULTS OF PHASE II STUDY
    Franzese, Ciro
    D'agostino, Giuseppe Roberto
    Liardo, Rocco Luca Emanuele
    Reggiori, Giacomo
    Navarria, Pierina
    Cristina, Iftode
    De Rose, Fiorenza
    Franceschini, Davide
    Tozzi, Angelo
    Comito, Tiziana
    Ascolese, Anna Maria
    Tomatis, Stefano
    Cozzi, Luca
    Scorsetti, Marta
    ANTICANCER RESEARCH, 2016, 36 (05) : 2545 - 2545
  • [6] Phase I dose-escalation study of stereotactic body radiation therapy for low- and intermediate-risk prostate cancer
    Bremer, M.
    STRAHLENTHERAPIE UND ONKOLOGIE, 2012, 188 (02) : 192 - 193
  • [7] Phase I Dose-Escalation Study of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer
    Boike, Thomas P.
    Lotan, Yair
    Cho, L. Chinsoo
    Brindle, Jeffrey
    DeRose, Paul
    Xie, Xian-Jin
    Yan, Jingsheng
    Foster, Ryan
    Pistenmaa, David
    Perkins, Alida
    Cooley, Susan
    Timmerman, Robert
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2020 - 2026
  • [8] Stereotactic Body Radiotherapy for Localized Low-Intermediate Risk Prostate Cancer
    Haas, J.
    Santoro, M.
    Ashley, R.
    Mucciolo, R.
    Andrews, J.
    Clancey, O.
    Episcopia, K.
    Accordino, D.
    Sanchez, A.
    Witten, M.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S432 - S432
  • [9] Phase 2 Multicenter Trial of Heterogeneous-dosing Stereotactic Body Radiotherapy for Low- and Intermediate-risk Prostate Cancer: 5-year Outcomes
    Fuller, Donald B.
    Falchook, Aaron D.
    Crabtree, Tami
    Kane, Brent L.
    Medbery, Clinton A.
    Underhill, Kelly
    Gray, James R.
    Peddada, Anuj
    Chen, Ronald C.
    EUROPEAN UROLOGY ONCOLOGY, 2018, 1 (06): : 540 - 547
  • [10] Stereotactic Body Radiation Therapy for Low- to Intermediate-risk Prostate Adenocarcinoma
    Jeong, Bae-Kwon
    Jeong, Hojin
    Ha, In Bong
    Choi, Hoon Sik
    Kam, Sung Chul
    Hwa, Jeong Seok
    Hyun, Jae Seog
    Chung, Ky Hyun
    Choi, See Min
    Kang, Ki Mun
    JOURNAL OF KOREAN MEDICAL SCIENCE, 2015, 30 (06) : 710 - 715
12345